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Summary 
 
Parkinson’s disease (PD) affects over 500,000 
Americans. Most cases of PD are idiopathic, or 
occurring without a known cause. Two pathological 
features of PD, α-synuclein-rich Lewy bodies (LB) 
and oxidative damage, hint at the cause of the 
disease. Yet, disparities in recessive forms of PD 
increase the complexity of the disease mechanism. 
These recessive forms occur earlier in life and are 
devoid of LB. One common feature among these 
forms is the extensive presence of reactive oxygen 
species (ROS). Studies with the toxin MPTP 
produced similar pathologies to recessive PD   but 
intriguingly showed inhibition of complex I in the 
mitochondria. These and other studies chased the 
mitochondria as the progenitor of oxidative stress. 
These investigations also uncovered several 
disparate mitochondrial proteins, one of which is a 
Kreb’s cycle enzyme, α-ketoglutarate 
dehydrogenase (α-KGDH). Interestingly, α-KGDH 
activity is reduced in both Alzheimer’s disease (AD) 
and PD. Links to both diseases may be due to its 
role in the inactivation of complex I. This review will 
focus on how mitochondrial impairments enhance 
neuronal toxicity in PD.        
 
Introduction 
 
Neurodegenerative diseases (NDD) are incurable, 
progressive, and fatal disorders of the central nervous 
system (CNS; Muchowski, 2002). Alongside this 
commonality, a culprit protein is frequently found 
tangled in symptomatic patients. Protein accumulation 
and subsequent aggregation is correlated with cell 
death in brains of the afflicted. Alzheimer’s disease 
(AD) and Parkinson’s disease (PD) are both NDD that 
have key similarities and differences. Investigations in 
both diseases have elucidated complementary 
mechanisms involving different genes.  
 In both AD and PD brains, insoluble protein 
deposits of tau and α-synuclein are, respectively, found 
(Caughey et. al., 2003; Dauer and Przedborski, 2003). 
In conjunction with protein aggregation, the 
accumulation of toxic oxidants, like superoxide and 
hydrogen peroxide, is another hallmark of both 
diseases (Mizuno et. al., 1995). Yet, the specificity of 
degeneration is unique to each disorder; AD has global  
neuronal death in the CNS, whereas PD has localized 
death (Caughey et. al., 2003). These similarities and 
differences have led scientists on a search to find the 
genes implicated in both diseases. This review will span 
the discoveries made in PD that point to dysfunctions in 
the mitochondria and its respiratory chain, some of 
which are also found in AD.   
 
 
* This paper was written for BIOL493, taught by Dr. Shubhik K. 
DebBurman. 
 
 
Parkinson’s Disease Etiology  
 
PD is a movement disorder characterized by a triad of 
symptoms: bradykinesia, postural rigidity, and resting 
tremors (Dauer and Przedborski, 2003). Voluntary 
movement is disrupted by the loss of dopamine in the 
intact striatum. Specific death of dopamine-producing 
neurons in the substantia nigra pars compacta (SNpc) 
leads to this loss-of-function phenotype (Dauer and 
Przedborski, 2003). α-Synuclein-dominant protein 
inclusions, or Lewy bodies (LB), are suspect in causing 
neuronal death in PD (Spillantini et. al., 1997). 
Additionally, post-mortem PD reveals oxidative damage 
partially due to redox-sensitive dopaminergic neurons 
(Beal, 2003). Yet, an exact mechanism that engages α-
synuclein-toxicity with oxidative stress has not been 
determined.  
 Sporadic mutations in α-synuclein constitute 
95% of PD cases. The other 5% of occurrences are 
attributed to a mixture of dominant and recessive 
genes. Dominant forms of PD have familial mutations in 
α-synuclein which increase its tendency to aggregate 
and form LB. Yet, recessive forms of PD are LB 
negative where the onset of symptoms occurs much 
earlier than in familial dominant forms. Two of these 
recessive genes, DJ-1 (Bonifati et. al., 2003) and 
PINK1 (Valente et. al., 2004), are involved in 
mitochondrial protection. Perturbations in these genes 
can impair mitochondrial function and lead to apoptosis 
and rapid generation of reactive oxygen species (ROS; 
Dauer and Przedborski, 2003). Whether or not α-
synuclein is involved in the mitochondrial disease 
pathway is unresolved. Dominant and recessive forms 
of PD may involve two different mechanisms that 
achieve the same symptoms. Both mechanisms, 
however, will have oxidative stress as a key player in 
PD pathogenesis.  
 
Oxidative Stress: The Main Cause of PD? 
 
The question remains: does the accumulation of ROS 
initially cause specific nigrostriatal death in PD? Studies 
performed with the toxin MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) have yielded support for this 
hypothesis (Langston et. al., 2003). The elucidation of 
PD pathogenesis has been largely dependent on the 
introduction of MPTP. 
 MPTP gains toxicity when converted to MPP+ 
(1-methyl-4-phenylpyridinium ion) by monoamine 
oxidase B (Chiba et. al., 1984). MPP+ is transported in 
neurons through a dopamine transporter (DAT; Chiba 
et. al., 1985). This is the only way MPP+ can enter a 
cell; thus, specific dopaminergic cell death can be 
ascribed by this quality. Complex I of the electron 
transport chain is inhibited by MPP+ (Nicklas et. al., 
1985). The inhibition of oxidative phosphorylation has 
many harmful effects including: decreased ATP 
production and increased oxidant production. This toxic 
state is further insulted by increased intracellular 
calcium, which enhances the release of dopamine to 
further promote oxidative damage (Fiskum et. al., 
2003). It is uncertain whether idiopathic PD is causally 
related to dopaminergic loss by complex I inhibition 
(Abou-Sleiman et. al., 2006). Regardless of the 
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pathway, oxidative modification plays an intimate role in 
the PD pathogenesis.     
 Oxidative stress may play a role in SNpc 
specific atrophy. Neuromelanin, and its high iron 
content which pigments the SNpc, may provide a 
necessary oxidative stress mechanism to specifically 
destroy the SNpc (Zecca et al., 2006).  Iron may 
aggressively catalyze ROS generation from oxidized 
substrates by the Fenton reaction (Mizuno et. al., 
1995). The increase of reactive oxidants can be 
measured by cellular responses. One such response is 
superoxide dismutase activity (SOD). This enzyme’s 
activity is elevated in the SNpc in PD (Saggu et. al., 
1989). Saggu and colleagues (1989) reported that Mn 
SOD activity was elevated over Cu-Zn SOD levels. This 
finding is significant because Mn SOD is localized in the 
mitochondria. Another indication of increased oxidant 
presence is the reduction of antioxidants. Glutathione is 
found reduced in PD (Perry and Yong, 1986). These 
data suggest that increased ROS are present in the 
mitochondria in PD. MPP+, SOD, and glutathione all 
point to the mitochondria as a putative producer of 
ROS. 
  Respiratory failure and increased oxidative 
stress both characterize PD. Yet, which event comes 
first? Jenner and colleagues (1992) studied an 
analogous system, Lewy body disease, to answer this 
question. They found loss of both glutathione and 
complex I substrates, yet glutathione was slightly less 
than complex I. They concluded that oxidative stress 
precedes respiratory failure in a PD. Other groups, 
however, disagree with Jenner and colleagues’ 
conclusions.  
 PD has a twofold loss of respiratory activity, 
which may exceed glutathione loss. The Kreb’s cycle 
enzyme, α-ketoglutarate dehydrogenase (α-KGDH), is 
also found deficient along with inhibition of complex I 
(Mizuno et. al., 1994). In fact, reduction of respiratory 
activity may be even more deleterious than oxidative 
stress alone. Chance et. al., (1979) suggest that α-
KGDH and complex I inactivity triggers enhanced 
generation of oxidative stress. When the ETC slows 
down due to inadequate activities of complex I and α-
KGDH, the leaky mitochondrial membrane generates 
increased free radicals. Thus, oxidative stress alone is 
not enough to explain PD pathogenesis. A pathway 
including mitochondrial respiratory failures must be 
engendered to understand how radicals are produced 
and sustained. In the next section, radical production 
from dopamine metabolism further explains SNpc 
specific degeneration  
 
The SNpc is Sensitive to ROS: Dopamine Auto-
Oxidation 
 
Dopamine auto-oxidation has long been an attractive 
hypothesis for SNpc selective death due to its 
endogenous metabolism in the SNpc (Graham, 1978). 
Normal metabolism of dopamine produces hydrogen 
peroxide and superoxide radicals, which oxidize 
dopamine to form dopamine-quinone (Dauer et. al., 
2003). Dopamine-quinone then proceeds to disrupt all 
proteins with disulfide linkages (Dauer et. al., 2003). 
Auto-oxidation has thus had a three-fold effect on the 
cell. One, the disassembly of proteins with disulfide 
linkages places an unnecessary stress and load on the 
ubiquitin-proteasome protein degradation system (UPS; 
Dauer et. al., 2003). Two, ROS generated by dopamine 
metabolism increases general protein misfolding in the 
cell, thus further increasing the load onto the UPS. And 
three, dopamine-quinone, like MPP+, may inhibit 
mitochondrial complex I activity. Cumulatively, 
dopamine metabolism primes SNpc neurons for self-
destruction. Thus, programmed cell-death, induced by 
ROS and mitochondrial dysfunction, may lead to 
specific death of SNpc neurons.  
 In mitochondrial respiratory dysfunction, ATP 
production is decreased. The lack of energy supports 
the necrotic cell death hypothesis of PD neurons 
(Mizuno et. al., 2005). However, since PD is a 
progressive disease, occurring over a long period of 
time, cellular necrosis cannot be the only theory for 
SNpc atrophy in PD. The decrease of ATP levels 
perturbs calcium homeostasis, which activates 
apoptotic pathways. Low levels of ATP decrease 
sodium ion transport to the outside of the cell. Thus, 
sodium must be expelled by the exchange of 
extracellular calcium (Reeves et. al., 1992). As stated 
above, high levels of intracellular calcium create an 
excitotoxic environment. Calcium is a second 
messenger that activates many cellular signaling 
pathways. Most notably, degenerate proteases are 
activated which induce apoptosis (Mizuno et. al., 2005). 
Furthermore, disruption in calcium homeostasis 
increases ROS production by the mitochondria. 
Imbalances in calcium homeostasis from mitochondrial 
respiratory failure feedback into the mitochondria and 
further degrade its normal activity (Mizuno et. al., 2005).     
 To further support the apoptosis based cell-
death scheme in PD, Hartmann et. al. (2001), describe 
the proapoptotic mitochondrial mediator, Bax, a 
member of the Bcl-2 family of proteins. Its primary role 
in cell death is to release cytochrome c from the inner 
mitochondrial membrane, in effect, purging its 
potentiation. This facilitates the activation of caspases, 
a group of cysteine proteases, which cleave numerous 
cellular proteins. They found that Bax levels were 
significantly higher in dopaminergic neurons containing 
LB than in overall melanized areas. These and other 
studies have strongly suggested dopamine’s role in 
SNpc specific cell death. These data support that 
dopamine metabolism enhances toxic ROS levels.  
 Collectively, mitochondrial deficiencies and 
dopamine metabolism leave PD neurons in a 
compromised state. We are still uncertain as to the 
exact role of the mitochondria in PD. The next section 
will explore the biochemical aspects of mitochondrial 
dysfunction.  
 
The Science behind Mitochondrial Dysfunction 
  
The mitochondrion is the gate keeper for ROS 
production. Significant rises in oxidative damage can 
only occur through deficiencies in respiratory 
metabolism (Cookson, 2005). Since oxidant levels are 
raised in the SNpc due to dopamine metabolism, SNpc 
neurons are predisposed to increased oxidant damage. 
When neurons are incapable of reducing this oxidant-
rich environment, the mitochondria is deleteriously 
impacted. The mitochondrion fuels its own destruction 
by rapidly producing even more oxidants. Nevertheless, 
what structures and pathways engender this response?  
 Normally during oxidative phosphorylation, 
electrons travel along the respiratory chain to complex 
I, II, III, and IV, along with cytochrome c and 
ubiquinone. The chain is commonly characterized as 
“leaky”, which promotes the reduction of substrates, 
such as oxygen, thereby producing a superoxide 
molecule (O2•–). Iron-sulfur clusters within the 
complexes provide the donation of one electron to 
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make the toxic superoxide molecule. This donation 
increases in probability as the ETC becomes more and 
more inhibited. The inhibition of the respiratory chain 
leaves upstream components reduced for relatively 
long periods of time. The escape of electrons is most 
favorable during this time. Consequently, since the 
redox potential decreases, electrons are not shuttled to 
the next carrier. The release of electrons in this window 
of time produces ROS (Adam-Vizi, 2005).  
Alternatively, superoxide production by 
complex I requires a pH gradient across the inner 
membrane space (Lambert et. al., 2004), which can be 
achieved with ubiquinone inhibitors. Ubiquinone is 
produced at two places in the ETC, complex I and 
complex II. ROS production requires inhibition of both 
sites so that ubiquinone is unable to carry electrons to 
complex III and continue to complex IV. If electrons are 
not shuttled to complex IV, oxygen is not reduced to 
water and remains saturated in the cell. Oxygen 
saturation is another prerequisite of ROS production 
(Boveris and Chance, 1973).  Thus, inhibition of 
complex I only is not adequate to produce toxic 
oxidants.   
Nonetheless, in the MPTP model of PD 
described above, MPP+ inhibits complex I. According to 
Lambert and colleagues (2004), complex I inhibition is 
not enough to produce superoxide radicals. The MPTP 
pathway must be developed further. Strikingly, MPP+ 
inhibits α-KGDH activity as well (McNaught et. al. 
1995). Reduction of α-KGDH thereby reduces 
succinate concentrations, the substrate for complex II. 
Succinate is then unable to carry electrons to complex 
II, in so doing inhibiting its activity. Thus, MPTP does, in 
effect, inhibit complex I and II (Figure 1).  
Until recently, the respiratory chain, or 
electron transport chain, has been assumed as the 
Figure 1. Effects of MPP+ Inhibition on Complex I and α-KGDH. A. Normal function of electron transport chain. B. MPP+ introduction into 
the mitochondria arrests ubiquinone (Q), thus electrons are not continuously transferred to complex III and IV. Oxygen is not reduced to 
water, so it is available for superoxide formation (O2•–). This inactivity disrupts the proton gradient needed to make ATP in complex V (not 
shown). 
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principal generator or ROS (Starkov et. al., 2004). 
Previous studies (Chance et. al., 1979) have suggested 
the duality of α-KGDH and complex I as sources of 
ROS. Yet, complex I-dependent ROS production was 
always thought to surpass α-KGDH-related ROS 
production. New evidence suggests that α-KGDH 
regulates complex I ROS production. In the next 
section, the relationship between α-KGDH and complex 
I activity will be discussed further.   
 
Non-Electron Transport Deficiencies: α-
Ketoglutarate Dehydrogenase 
 
The toxin MPTP serves as a convenient model for PD, 
but most cases are idiopathic. MPTP fails to replicate 
two other qualities of classical PD: Lewy body 
inclusions and progressive onset. MPTP-induced 
Parkinsonism occurs rapidly after exposure thus 
making it, at most, a model of PD. This begs the 
question, can complex I be inhibited by any other 
means? Extensive studies with the α-KGDH have 
revealed that possibility and more.  
 α-KGDH is regulated by the NADH/NAD+ 
ratio, Ca2+, and ADP (Adam-Vizi, 2005). Its loss-of-
function would thus eliminate a key modulating location 
in glucose metabolism. Interestingly, the isolated 
enzyme produces hydrogen peroxide and superoxide 
radicals (Tretter and Adam-Vizi, 2004). These results 
were found to hold true in situ as well (Starkov et. al., 
2004). This generation of ROS was dependent on the 
NADH/NAD+ ratio, where increasing NADH levels 
account for this phenomenon. Increasing ROS levels 
actually inhibit α-KGDH (Tretter and Adam-Vizi, 1999). 
The inhibition of α-KGDH reduces NADH for the ETC, 
thus decreasing ATP production. Consequently, by 
these inverse pathways, α-KGDH is both a target and 
generator of oxidative stress   
 Markedly, α-KGDH may regulate complex I 
activity by these inverse pathways (Adam-Vizi, 2005). 
As stated before, inhibition of α-KGDH reduces NADH 
production which kinetically decreases complex I 
(NADH ubiquinone oxidoreductase) activity. The other 
inhibitory pathway is set in motion by a high NADH 
concentration. Thus, complex I is kinetically active 
under these conditions. The generation of ROS by α-
KGDH in the mitochondrial matrix may disrupt complex 
I activity (Figure 2). Also, the ROS generated by α-
KGDH would increase lipid peroxidation thereby 
disrupting calcium homeostasis. Lipid disruption would 
furthermore perturb the pH gradient across the inner 
membrane space. This loss of membrane potentiation 
is a step towards apoptosis. Loss of α-KGDH activity 
and inhibition of complex I is a similar to the MPTP-
based model of PD. 
Figure 2. α-KGDH Regulation of Complex I Activity. A. ROS inhibits α-KGDH which decreases the production of NADH in the 
Kreb’s cycle. The lack of NADH lowers complex I activity, thus ATP is not synthesized. B. A high concentration of NADH increases 
the activity of both α-KGDH and complex I. Yet, this dual activation is counterintuitive. α-KGDH produces ROS when NADH levels 
are high. This may, in turn, inhibit previously activated complex I.   
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 Loss of α-KGDH also occurs in AD. Gibson 
and colleagues (1988) have demonstrated that α-
KGDH activity is reduced by 40-75% in AD brains. 
Reduction in α-KGDH levels is negatively correlated 
with neurofibrillary tau tangle counts, suggesting this 
enzyme is involved in the neurodegenerative cascade. 
Even 10 to 15% reduction in available glucose or 
oxygen can reduce brain function, including decline in 
memory (Gibson et. al., 2005). A current study shows 
how brain regions with low metabolic activity 
accumulate more plaques in conjunction with dementia 
(Shoghi-Jadid et. al., 2002). The return of glucose to 
these brain regions reverses some behavioral deficits 
found in AD. This suggests that symptoms in AD are 
not always attributed to neurodegeneration. The 
question remains, how does α-KGDH activity decrease 
in AD and PD? 
 Genetic studies have attempted to answer 
this question. Two different groups have attempted to 
track the allele responsible for α-KGDH deficiencies in 
AD and PD. Of the three subunits of α-KGDH, the 
second has received most attention because of its 
noted ROS producing activity (Starkov et. al., 2004). 
The other two subunits do not produce ROS. 
Polymorphisms on the second subunit have been 
paired with the apolipoprotein E4 gene in AD to cause 
dementia. Apolipoprotein E4 is not a factor on its own 
until it is paired with the α-KGDH polymorphism (Sheu 
et. al., 1998). Similarly, a bi-allelic intragenic 
polymorphism of α-KGDH was found to constitute a 
genetic risk factor for PD (Kobayashi et. al., 1998). The 
dysfunction of α-KGDH caused by the polymorphism 
suggests a causal genetic link to NDD. Whether α-
KGDH activity is inhibited by a genetic link or ROS 
remains to be determined.  
 Since the identification of α-KGDH as a 
critical enzyme in AD and PD pathogenesis, several 
studies have sought to reverse the phenotypes in these 
NDD. In PD, acute lipoic acid, a key cofactor for α-
KGDH, administration increases cerebral metabolism, 
thus reversing the α-KGDH deficit (Seaton et. al., 
1996). This was performed under the assumption that 
α-KGDH activity is decreased in PD brains. This study 
indirectly supports the α-KGDH-centric hypothesis of 
PD. Likewise, in AD, thiamine supplementation proved 
to have beneficial effects in patients (Mimori et. al., 
1996). Thiamine is necessary for α-KGDH activity, as 
well. Both of these studies support the hypothesis that 
α-KGDH is involved in AD and PD pathogenesis.  
 There are other mitochondrial connections to 
PD pathogenesis. Two recently discovered genes, 
when mutated, were found to cause LB negative 
Parkinsonism (Bonifati et. al., 2003; Valente et. al., 
2004), similar to MPTP models. The genes DJ-1 and 
PINK1 will be discussed next.  
 
Mitochondrial Links in PD Pathogenesis: DJ-1 and 
PINK1  
 
Mutations in DJ-1 and PINK1 cause loss of 
dopaminergic function (Cookson, 2005). Both genes 
produce proteins with different functions yet have 
similar phenotypes.  
 DJ-1 may normally modulate gene 
expression in the cytoplasm during cell stress (Bonifati 
et. al., 2003). Oxidation at C106 (Kinumi et. al., 2004) of 
DJ-1 causes it to localize to the outer membrane of 
mitochondria under oxidative conditions. There, it 
protects cells against complex I inhibitors. Thus, 
mutations at C106 inhibit this protective mechanism. 
DJ-1 is customarily oxidized in non cell death 
conditions. Accordingly, it’s localization to the outer 
membrane of mitochondria may suppress apoptosis 
(Canet-Aviles et al., 2004).  
 PINK1 is a serine/threonine kinase with an N-
terminal mitochondrial localization signal (Valente et. 
al., 2004). Valente and collegues (2004) also observed 
that PINK1 protects cells against apoptosis induced by 
proteasome inhibitors. The PINK1 substrate is still 
unknown as well as its protection specificity. One 
feature is clear, however, both DJ-1 and PINK1 protect 
against loss of mitochondrial function. 
 
Conclusion 
 
The redox status of a cell is delicately modulated by 
several mechanisms. Mitochondria play an integral part 
in this regulation. The loss-of-function of mitochondrial 
proteins like complex I, α-KGDH, and PINK1 have 
implications for the viability of cells in NDD. In PD, 
dopaminergic neurons respond to stress in a unique 
way. Dopamine metabolism decreases the oxidative 
stress threshold required for apoptosis. Thus, 
mitochondrial impairments selectively target 
dopaminergic neurons. These impairments, in turn, 
further devastate mitochondrial function. The slippery 
slope of cell death in PD is characterized by the 
additively detrimental interactions between oxidative 
stress and mitochondrial dysfunction.   
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